From May 19, 2021:
The aim of the COVID Moonshot initiative is to develop a globally accessible oral antiviral. In 1 year, Moonshot has gone from a fragment screen to several lead series. The initiative is currently optimising such leads and hopes to announce a preclinical candidate ready for clinical trial-enabling studies within 3 months.
Any updates?